Effect of Androgen–Androgen Receptor Directed Therapy on COVID-19 Outcome in Prostate Cancer Patients. (2nd January 2023)

• Record Type: Journal Article
• Authors: Ünlü, Serhan; Shin, Junghee Jenny; Par-Young, Jennefer; Simonov, Michael; Vinetz, Joseph; Petrylak, Daniel P.; Kang, Insoo; Kim, Joseph W.
• Is Part Of: Cancer investigation. Volume 41:Number 1(2023)
• Page Start: 77
• Page End: 83
• Publication Date: 2023-01-02
• Subjects: COVID-19 -- androgen deprivation therapy -- prostate cancer; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2022.2139839
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: TMPRSS2 is utilized by SARS-CoV-2 for cellular entry. Androgen-Androgen receptor directed therapy (A/ARDT) downregulates expression of TMPRSS2. We hypothesized A/ARDT might protect prostate cancer (PCa) patients from poor COVID-19 outcome. A retrospective analysis of PCa patients with COVID-19 infection was performed. 146 PCa cases were identified, 17% were on A/ARDT. Hospitalization rates were same 52% (OR = 0.99, 0.41–2.24). Mean hospitalization was 9.2 (Range: 1–25) and 14.9 (Range: 2–47) days in A/ARDT and non-A/ARDT groups, respectively. While definitive conclusions cannot be made regarding outcome differences between groups due to lack of statistical significance, these data generate hypothesis that A/ARDT might shorten hospitalization stay.